Literature DB >> 30488628

Letter: vedolizumab drug concentrations in neonates following intrauterine exposure.

Emma Flanagan1, Peter R Gibson2, Jakob Begun3, Simon Ghaly4, Mayur Garg5, Jane M Andrews6, Ourania Rosella7, Gennaro Rosella7, Sally J Bell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30488628     DOI： 10.1111/apt.15027

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  4 in total

Review 1.  Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

2.  Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.

Authors:  Birgit Terjung; Renate Schmelz; Robert Ehehalt; Jochen Klaus; Jana Knop; Sabine Schwind; Thomas Wilke; Andreas Stallmach
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

Review 3.  Pregnancy and Crohn's disease: concerns and assurance of medical therapy.

Authors:  Reezwana Chowdhury; Sunanda V Kane
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-10-10

4.  Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review.

Authors:  N Ghalandari; R J E M Dolhain; J M W Hazes; E P van Puijenbroek; M Kapur; H J M J Crijns
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.